Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-06439535 vs bevacizumab-EU plus paclitaxel/carboplatin in non-squamous NSCLC
CTR20192191Phase 3Terminated
- Sponsor
- GE HealthCare
- Start
- Nov 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of bevacizumab-bvzr, bevacizumab in Non-small cell lung cancer (NS-NSCLC), sponsored by GE HealthCare. Started Nov 2019; status: terminated.
02
Drugs
bevacizumab-bvzrbevacizumab
03
Conditions
Non-small cell lung cancer (NS-NSCLC)
Beyond the preview
Go deeper on CTR20192191.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20192191.